Advisers used tough tactics to bring desired trade deals to the president, but key details in many remain unfinished.

Kennedy’s $500M cut to mRNA funding puts startups at risk and imperils one of life sciences’ few leasing bright spots.

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s ...

Fintel reports that on August 8, 2025, JP Morgan upgraded their outlook for Sanofi - Depositary Receipt () (NasdaqGS:SNY) from Neutral to Overweight. Analyst Price Forecast Suggests 34.83% Upside As ...

Children with moderate/more extensive atopic dermatitis treated with ruxolitinib cream achieved significant disease control ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

NEW YORK (Reuters) -Woes for U.S. healthcare stocks have worsened this year driven partly by Trump administration policies, ...

O'Reilly Automotive Inc. is suing the three major pharmacy benefit managers in the U.S., as well as the three major insulin manufacturers.

HHS Secretary Robert F. Kennedy Jr. says the federal government is calling off around $500 million worth of vaccine ...

Drugmakers Sanofi, Eli Lilly, Novo Nordisk and AstraZeneca must face a lawsuit from two health centers accusing them of ...